United Therapeutics Corporation (UTHR) Stock Analysis

72.0/100
Buy Not Halal Healthcare
Price $591.17
Market Cap $25.18B
52-Week Change +27.88%

Is UTHR a good investment?

United Therapeutics Corporation (UTHR) has a Plutrex AI rating of 72.0/100 as of November 04, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Profitability fortress unmatched in biotech: net margin 41.56% vs. industry 1.71% (2,330% premium), operating margin 42.23% vs. industry -90.0% (132pp above), gross margin 86.1% — these margins are sustained by Tyvaso's entrenched PAH franchise and reinforced by the Liquidia patent settlement that protects exclusivity under favorable licensing terms. Main concern: Structural growth deficit — entirely unchanged and worsening in valuation terms: Revenue growth -1.9% YoY (UNCHANGED), 5-year EPS CAGR 9.73% (UNCHANGED), PEG 2.21x (WORSENED from 2.18x), and the stock has risen +1.4% since the prior report with ZERO fundamental improvement — the market is continuing to price in a growth premium that the fundamentals do not support; EPS growth above the 9.7% baseline is achievable only via buybacks and margin management, not organic top-line recovery.

Investment Summary

United Therapeutics (UTHR) at $601.32 is a world-class pharmaceutical franchise with exceptional quality metrics — gross margin 86.1%, net margin 41.6%, operating margin 42.2%, zero debt, $2.66B cash, $1.09B annual FCF — but trading at a growth-adjusted premium (PEG 2.21x on 5-year EPS CAGR 9.7%) with negative revenue growth (-1.9% YoY) that creates a structurally unattractive entry point at current levels. Since the prior report 8 days ago, the stock has risen another +1.4% ($592.84 → $601.32), P/E has expanded from 21.21x to 21.48x, and PEG has edged from 2.18x to 2.21x — all on ZERO fundamental improvement. Revenue growth (-1.9%), analyst target ($666), and 5-year EPS CAGR (9.7%) are completely unchanged. The $2B share repurchase program, FDA SUMMIT trial clearance for treprostinil SMI in a new indication, and expansion of xenotransplantation manufacturing capacity are genuine positives but were already reflected in the prior 72/100 rating. The gap to analyst consensus has narrowed further from ~12.3% (at $592.84) to ~10.8% (at $601.32), compressing the risk/reward to approximately 1.4-1.5x at current price vs. a stop near $550 support. The stock remains a HOLD for existing shareholders on the basis of buyback support and quality moat, but new entries are not justified above $580.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
92/100
Growth Potential
32/100
Valuation
36/100
Profitability
96/100
Debt Management
98/100
Analyst Sentiment
72/100
Technical Momentum
60/100
Insider Confidence
62/100
News Sentiment
75/100

Fundamental Analysis

UTHR's fundamentals are unchanged from the prior report and remain exceptional in absolute terms but structurally problematic relative to its current valuation. P/E of 21.48x (vs. biotech industry 26.00x — a 17.4% discount on headline P/E) appears reasonable, but the PEG ratio of 2.21x (vs. industry 2.01x — a 9.7% PREMIUM) exposes the core problem: UTHR is paying more on a growth-adjusted basis than the average biotech despite delivering only 26.4% of the sector's forward EPS growth (14.67% vs. industry 55.59%) and only 45.1% of the sector's 5-year EPS CAGR (9.73% vs. industry 21.55%). Revenue growth of -1.9% vs. industry average of +192.66% (skewed by high-growth early-stage peers, but illustrative) underscores that UTHR is a mature franchise, not a growth story. On the quality side: gross margin 86.1% (vs. industry 80.0%), operating margin 42.23% (vs. industry -90.0%), net margin 41.56% (vs. industry 1.71%), ROE 19.32% (vs. industry -2.27%), zero debt (D/E = 0.00 vs. industry 0.208), $2.66B cash, $1.09B FCF. These are elite-tier metrics. The divergence between -1.9% revenue growth and +9.1% EPS growth reflects margin management and buyback activity — admirable short-term but unsustainable if top-line contraction continues. Graham-style intrinsic value at 15-20x FCF ($1.09B) yields $16.4B-$21.8B enterprise value; quality-adjusted fair value with a 20% premium for the fortress balance sheet lands near $566-$572, suggesting the stock at $601.32 is modestly above quality-adjusted fair value.

News Sentiment

United Therapeutics is quietly building its future while protecting its present — and Wall Street is watching closely. The Pennsylvania-based biotech has been making a series of strategic moves that signal both confidence and caution. The company recently announced a massive $2 billion share buyback program, one of the largest in its history, essentially telling investors: 'We believe in this stock.' That kind of corporate conviction matters, especially when analysts are projecting a near-term earnings dip. Speaking of which, analysts have flagged that United Therapeutics may report a decline in upcoming earnings — a headline that sounds alarming but is partly expected given the competitive dynamics in its core pulmonary arterial hypertension (PAH) drug market, where rival Liquidia's settlement means a licensed competitor will eventually enter. On the pipeline front, the FDA has given the green light for the company's SUMMIT clinical trial — a Phase 2 study testing treprostinil in a soft mist inhaler format for a new group of roughly 40 patients. This is smart science: using a proven drug in a new delivery system reduces the risk of failure compared to developing a brand-new molecule. Meanwhile, United Therapeutics opened its third organ manufacturing facility, named after pioneering transplant surgeons, deepening its bet on xenotransplantation — the sci-fi-sounding but very real effort to use genetically modified pig organs for human transplants. The Liquidia settlement, while giving a competitor a path to market, was interpreted by markets as removing a major legal overhang — Liquidia shares jumped 25% on the news. For United Therapeutics, the settlement provides clarity and licensing income. The overall picture: a mature, cash-rich company buying time and building optionality while its core franchise navigates competitive pressure.

Risk Assessment

PRIMARY RISK: Revenue contraction (-1.9% YoY) proves structural rather than cyclical — if Tyvaso revenues erode faster than the buyback and margin management can offset, EPS growth collapses below the 9.7% CAGR baseline, triggering a de-rating from P/E 21.48x toward a more appropriate 15-17x for a flat/declining revenue business, implying a price range of $420-$475 (20-30% downside). SECONDARY RISK: At PEG 2.21x with 10.8% upside to consensus, any earnings miss or guidance reduction would remove the buyback floor psychology and compress the multiple rapidly — the stock has limited cushion at $601. MITIGATION: The $2B buyback provides a mechanical EPS support floor; the Liquidia settlement (favorable terms) reduces the probability of a sharp Tyvaso revenue cliff; SUMMIT trial success (Phase 2 readout) could provide a re-rating catalyst above $666 consensus if it demonstrates efficacy in new indication. TECHNICAL RISK: The stock is 1.4% above the prior report price with declining momentum (technical_momentum_rating lowered to 60 from 62); a failure to maintain $590 support opens a move toward $550-$555, which is both technical support and the quality-adjusted fair value entry zone. POSITION SIZING: 3% allocation appropriate for a Weak Hold — large enough to participate in potential buyback-driven upside but small enough to allow averaging down at $555-$566 if the entry zone is reached.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is UTHR a halal stock?

No, United Therapeutics Corporation (UTHR) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for UTHR?

United Therapeutics Corporation (UTHR) has a Plutrex AI rating of 72.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is UTHR a good investment?

According to Plutrex AI, UTHR has a Buy rating (72.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in UTHR?

US stocks like UTHR can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in UTHR?

Plutrex AI identifies the main risks for UTHR by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about UTHR

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open UTHR in ElBarake